Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results

February 22, 2017 5:52 AM

Mizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found